Davis Polk advised the underwriters in connection with the $34.5 million public offering of 13,800,000 common shares of Affimed N.V. The offering included 1,800,000 common shares sold by Affimed pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The common shares are listed on the Nasdaq Global Market under the symbol “AFMD.”

Based in Heidelberg, Germany, Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells.

The Davis Polk corporate team included partner Derek Dostal and associate Dan Gibbons. The tax team included partner Patrick E. Sigmon. The intellectual property and technology team included partner David R. Bauer and associate Jesse L. Hallock. All members of the Davis Polk team are based in the New York office.

Copy link to share post